Journal
CHEMOTHERAPY
Volume 67, Issue 2, Pages 81-90Publisher
KARGER
DOI: 10.1159/000521751
Keywords
Gastrointestinal stromal tumours; KIT; Exon 9; Treatment; Imatinib
Categories
Funding
- Royal Marsden/Institute of Cancer Research National Institute for Health Research Biomedical Research Centre
Ask authors/readers for more resources
Exon 9-mutant GISTs represent a distinct subtype of GISTs that differ from other GIST subtypes, including the more common KIT exon 11-mutant GISTs. A better understanding of the molecular biology and clinical behavior of exon 9-mutant GISTs may help identify more improved treatment options.
Background: The majority of gastroinstestinal stromal tumours (GISTs) harbour oncogenic mutations in the gene encoding for the tyrosine kinase (TK) KIT. The most common mutations are found in exon 11, followed by mutations in exon 9. The latter mutations are associated more frequently with GISTs in extra-gastric locations and with a more aggressive clinical behaviour. Summary: Here, we review the unique and often poorly recognized molecular, biological, and clinical characteristics that differentiate KIT exon 9-mutant GISTs from other GIST subtypes. In particular, KIT exon 9 mutations are associated to KIT mutants with retained sensitivity to stimulation by stem cell factor and localization to the cell membrane. Moreover, KIT exon 9-mutant GISTs display significant activation of KIT-independent oncogenic pathways. These characteristics may explain the limited activity of the TK inhibitor imatinib in the adjuvant setting in KIT exon 9-mutant GISTs, as well as their lower sensitivity to standard dose imatinib in the advanced setting. In contrast, the multi-TK inhibitor sunitinib displays better activity in KIT exon 9-mutant GISTs compared to others. Key Messages: exon 9-mutant GISTs represent a subtype of GIST distinct from other GISTs, including the more common KIT exon 11-mutant GISTs. A better understanding of the molecular biology and clinical behaviour of KIT exon 9-mutant GISTs may help identify more improved treatment options. (C) 2022 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available